A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG)

Pediatric Blood and Cancer

Volumn 60, Issue 1, 2013, Pages 71-76

  Yalon, Michal ^a   Rood, Brian ^b   Macdonald, Tobey J ^c   Mccowage, Geoff ^d   Kane, Rochelle ^b   Constantini, Shlomi ^e   Packer, Roger J ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Erlotinib; Low grade gliomas; Tarceva

Indexed keywords

BEVACIZUMAB; ERLOTINIB; RAPAMYCIN;

ADOLESCENT; APHTHOUS ULCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CELLULITIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLIOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MULTIPLE CYCLE TREATMENT; NEUROFIBROMATOSIS; NEUTROPENIA; PARONYCHIA; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84870188356     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24142     Document Type: Article

References (33)

1. Waliner KE, Gonzales MF, Edwards MS, et al. Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988; 69: 171-176.
2. Allen JC. Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg 2000; 32: 154-162.
3. Wisoff JH, Sanford R, Holmes E, et al. Impact of surgical resection on low grade gliomas of childhood: A report from the CCG9891/POG 9130 low grade astrocytoma study. Presented at the Tenth International Symposium on Paediatric Neuro-Oncology. London. 2002; June 9-12.
4. Merchant TE, Kun LE, Wu S, et al. Phase II trial of conformal radiation therapy for pediatric low-grade gliomas. J Clin Oncol 2009; 27: 3598-3604.
5. Marcus KJ, Goumnerova L, Billett AL, et al. Stereotactic radiotherapy for localized low-grade gliomas in children: Final results of a prospective trial. Int J Radiat Oncol Biol Phys 2005; 61: 374-375.
6. Duffner PK, Cohen ME. Long-term consequences of CNS treatment for childhood cancer, Part II: Clinical consequences. Pediatr Neurol 1991; 7: 237-242. Review.
7. Merchant TE, Conklin HM, Wu S, et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 2009; 27: 3691-3697.
8. Pascual-Castroviejo I, Pascual-Pascual SI, Velázquez-Fragua R. et al. Neurofibromatosis type 1 and optic pathway gliomas: A series of 80 patients [in Spanish]. Rev Neurol 2008; 46: 530-536.
9. Cappelli C, Grill J, Raquin M, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child 1998; 79: 334-338.
10. Guillamo JS, Créange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients. Brain 2003; 126: 152-160.
11. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86: 747-754.
12. Ater J, Holmes E, Zhou T. et al. Results of COG protocol A9952: A randomized phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children. Neuro Oncol 2008; 10: 451 (abstr LGG18).
13. Gnekow AK, Kortmann RD, Pietsch T, et al. Low grade chiasmatic-hypothalamic glioma-Carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy: Report from the multicenter treatment study for children and adolescents with a low grade glioma, HIT-LGG 1996, of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004; 216: 331-342.
14. Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005; 103: 2636-2642.
15. Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997; 32: 235-241.
16. Hsu TR, Wong TT, Chang FC, et al. Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst 2008; 24: 1457-1461.
17. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002; 20: 4209-4216.
18. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro-Oncol 2007; 9: 161-168.
19. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791-795.
20. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clic Cancer Res 2008; 14: 3386-3394.
21. Budk E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-2684.
22. Gemmill RM, Zhou M, Costa L, et al. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer 2005; 92: 2266-2277.
23. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005; 4: 101-112.
24. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 2010; 96: 219-230.
25. Price KA, Azzoli CG, Krug LM, et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 1623-1629.
26. Broniscer A, Panetta JC, O'Shaughnessy M, et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13: 1511-1515.
27. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848.
28. Hata A, Kaji R, Fujita S, et al. High-dose Erlotinib for refractory brain metastases in a patient with relapsed nonsmall cell lung cancer. J Thorac Oncol 2011; 6: 653-654.
29. Clarke JL, Pao W, Wu N, et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99: 283-286.
30. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase 1 and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: A Children's Oncology Group phase 1 consortium study. J Clin Oncol 2008; 26: 4921-4927.
31. Inoki K, Ouyang H, Li Y, et al. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005; 69: 79-100.
32. Lee da Y, Yeh TH, Emnett RJ, et al. Neurofibromatosis-1 regulated neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev 2010; 24: 2317-2329.
33. Scholpp S, Lumsden A. Building a bridal chamber: Development of the thalamus. Trends Neuerosci 2010; 33: 373-380.